MannKind Corporation stocks have been trading up by 4.4 percent following upbeat news on its inhaled insulin Afrezza performance
Click Here for a Millionaire's POV on Trading MNKD
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
What Traders Need To Know
- MannKind will present nine new Afrezza and FUROSCIX data sets at ADA 2026, including pediatric, gestational, automated pump, and real-world outcomes data.
- The Afrezza pediatric sBLA has a PDUFA date of 2026/05/29, and approval would make it the first needle-free insulin for children and adolescents.
- A CEO fireside chat at the 2026 Jefferies Global Healthcare Conference will spotlight MannKind Corporation’s cardiometabolic and orphan lung focus.
- Multiple Form 4 insider filings show changes in MNKD beneficial ownership, but with no detail on trade size, price, or buy/sell direction.
Weekly Update May 25 – May 29, 2026: On Friday, May 29, 2026 MannKind Corporation stock [NASDAQ: MNKD] is trending up by 4.4%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Healthcare industry expert:
Analyst sentiment – positive
MannKind sits in a niche cardiometabolic and pulmonary drug‑device segment with differentiated assets but still subscale economics. Revenue of ~$349M with 3‑year CAGR >40% signals strong top‑line growth, yet EBIT margin (-6.6%) and pretax margin (-13.9%) show the model is not self‑funding. Gross margin near 100% reflects high Afrezza royalty and device economics, but SG&A at ~60% of revenue and negative FCF (Q1 FCF about -$7M) keep leverage high and equity negative.
Weekly price action from ~$3.54 to $3.81 shows a clear short‑term uptrend with higher highs and higher lows, confirming accumulation ahead of catalysts. Intraday 5‑minute candles show orderly dips being bought rather than distribution, with volume expanding on pushes above $3.70–3.75. The actionable level is $3.70: above this, momentum buyers should target a test of $4.20–4.30, while a decisive break back below $3.50 would invalidate the bullish setup and favor a quick exit.
More Breaking News
- ServiceNow Stock Jumps As Experian AI Deal Fuels Momentum
- CDT Equity Jumps As AZD5904 Patent Wins Fuel Licensing Hopes
- Sunlands Technology Group Sets Earnings Date As STG Price Spikes
- INFQ Stock Surges On $100M Quantum Funding LOI
Near‑term upside is dominated by the Afrezza pediatric sBLA PDUFA on May 29, 2026, plus nine ADA data sets that can broaden prescriber comfort and payer traction; approval would materially expand Afrezza’s addressable market versus typical small‑cap biotech single‑asset risk. Sector‑wise, MNKD screens higher growth but weaker profitability than large‑cap healthcare and mid‑cap biotech peers. I see an asymmetric long: buy with support at $3.50, resistance at $4.50, 6–12 month fair value in the $5.00–5.50 range on successful pediatric approval.
Quick Financial Overview
MannKind Corporation (MNKD) is trading in a steady uptrend, with weekly prices lifting from the mid-$3.50s to a recent close around $3.81–$3.83. Intraday, the stock held a broad range between roughly $3.56 and just under $3.92, but kept reclaiming dips and grinding higher into the close. That pattern shows active two-sided trading, yet buyers are still in control as price rides above earlier support near $3.65–$3.70.
On the fundamental side, MannKind delivered about $349.0M in trailing revenue, with revenue growth above 40% over both three- and five-year windows. Gross margin is extremely high, near 99.7%, which is typical for a drug-device model once fixed costs are covered. At the same time, the company is not yet consistently profitable, with recent EBIT margin around -6.6% and a quarterly net loss near $16.6M.
Cash and liquidity are workable but not massive. Current ratio near 1.9 and quick ratio around 1.2 give MannKind Corporation some room, though leverage is meaningful with long-term debt above $329.0M. Operating cash flow last quarter was about -$5.4M, and free cash flow was roughly -$7.2M, which means the story still leans on growth and future scale rather than current earnings strength. For traders, that combination often amplifies reaction to clinical and regulatory headlines like the Afrezza pediatric sBLA.
Conclusion
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.